drugset / Trial / NCT00267176

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

NCT00267176

Phase 4 Completed 1020 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the effect on ambulatory blood pressure of lumiracoxib 100 mg once daily versus ibuprofen 600 mg three times a day in osteoarthritis patients with controlled hypertension.

Timeline

Start
2005-11
Primary completion
2006-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lumiracoxib Small molecule 100 mg